Tower Research Capital (TRC)’s BioLineRX BLRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-39	Closed	-$147	–	5163
2025 Q3	$147	Buy	+39	New	+$156	﹤0.01%	5090
2022 Q3	–	Sell	-18	Closed	-$1K	–	6066
2022 Q2	$1K	Buy	+18	New	+$1K	﹤0.01%	5738
2016 Q1	–	Sell	-3	Closed	-$2K	–	4131
2015 Q4	$2K	Buy	+3	New	+$2.49K	﹤0.01%	3689
2015 Q1	–	Hold	0	–	–	–	4409
2014 Q4	–	Sell	-7	Closed	-$6.08K	–	4028
2014 Q3	$7K	Buy	+7	New	+$7.52K	﹤0.01%	3056
2014 Q1	–	Sell	-17	Closed	-$28K	–	4447
2013 Q4	$28K	Buy	17 +14	+467%	+$22.6K	﹤0.01%	1950
2013 Q3	$4K	Buy	+3	New	+$3.54K	﹤0.01%	3771

Other funds holding BLRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Tower Research Capital (TRC)'s BLRX Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of BioLineRX (BLRX) in Q4 2025, closing a stake of 39 shares — an estimated $147 sold.

Tower Research Capital (TRC) first reported a position in BLRX in Q3 2013 and held it in 6 quarters. The position peaked at $28K in Q4 2013. 14 funds tracked by Wall St. Rank hold BLRX as of Q4 2025.

Tower Research Capital (TRC) reported no remaining BioLineRX position as of Q4 2025 after selling out during the quarter.
Tower Research Capital (TRC) sold 39 BioLineRX shares in Q4 2025, an estimated $147.
Tower Research Capital (TRC) first reported a position in BioLineRX in Q3 2013 and held it in 6 quarters.
Tower Research Capital (TRC)'s BioLineRX position peaked at $28K in Q4 2013.
14 funds tracked by Wall St. Rank held BioLineRX as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.